Rhythm partners with NHS England Southern Hub to independently evaluate ColoSTAT® for potential use in the bowel cancer screening pathway — an important step toward international commercialisation. #ColoSTAT #RHY #CancerScreening #NHS #Diagnostics

Rhythm Biosciences partners with Catch Bio to offer both geneType™ and Catch Bio’s AI-powered prevention model to US members — strengthening proactive cancer risk assessment and advancing our US expansion. #RHY #geneType #CancerPrevention #HealthTech

Rhythm Biosciences achieves the geneType™ laboratory to ISO15189:2022 standard after NATA reassessment audit. This milestone ✔Aligns operations under one standard ✔Supports progression of ColoSTAT® as an in-house IVD (pending NATA variation Read update: https://t.co/K1qTHtQuXD

geneType® Ovarian Cancer risk model has been cross validated in the Nurses’ Health Study and published in Cancer Prevention Research. This strengthens the evidence for geneType and supports its role in personalised, risk-stratified cancer prevention. Read: https://t.co/iAGvX6IrAN

The Australian DOH has released new breast density guidance for GPs. Nearly 50% of women have dense tissue, which increases cancer risk and reduces mammogram sensitivity. Using validated risk tools that include breast density can help identify who may need supplemental imaging.

Great discussions at The Menopause Society meeting in Orlando! GeneType® supports proactive women’s healthcare by helping clinicians identify disease risk earlier and guide prevention. To learn more or become a provider : https://t.co/yK1BUMJRcH #WomensHealth #GeneType

Honoured to join #CoLab2025 in Wellington — bringing together leaders & innovators shaping the future of pathology and lab medicine in NZ. Huge thanks to @Awanui & the organising team for an inspiring event. To learn more: https://t.co/3NQ9xOMRJq #GeneType#CoLab2025

October is #BreastCancerAwarenessMonth We’re proud to partner with @KnowYourLemons to help women understand their unique risk and take action. Knowing your risk is life-saving. Learn more: https://t.co/gHj6xG344W #KnowYourRisk #GeneType #BreastCancerAwareness

Breast health awareness starts with knowing your body. Early detection makes a difference - Stage 1 breast cancer has a 99% five-year survival rate. Monthly self-exams help you notice changes @knowyourlemons for how to check: https://t.co/G0OGNd56hE #breastcancerawareness

Important conversations about #breastcancer risk shouldn't wait. Our blog covers key questions to discuss with your healthcare provider like understanding personal risk factors to genetic testing options like BRCA1/BRCA2. Read https://t.co/Qt4D5ubVmZ #genetype $RHY

This #WomensHealthWeek, consider how proactive health management includes understanding your genetic risk profile. geneType™ offers comprehensive risk assessment for breast #cancer, ovarian cancer, cardiovascular disease, diabetes and melanoma: https://t.co/xTkGAJUu5e

Annual Report: Strong 20-month progress across our cancer diagnostics platform. ColoSTAT® restructured with strong clinical performance, geneType™ acquisition delivering first revenues, strategic partnerships re-established. Read: https://t.co/p2ey3D9ZTw $RHY

Long Shortz with @rhythmbiosc : Non-invasive bowel cancer test delivers strong results https://t.co/n4y7ZPlZZU #ASX #Health $RHY

Rhythm enters co-marketing agreement with @knowyourlemons to promote geneType™ breast cancer risk assessment. Reaching hundreds of thousands of women through its mobile app and employee programs in the US. Perfect timing for #BreastCancerAwarenessMonth $RHY

Rhythm Biosciences completes final validation of ColoSTAT colon cancer test https://t.co/EUxaeG80aT #ASX #Biotech $RHY @rhythmbiosc

ColoSTAT® milestone - final validation complete and NATA application submitted. Over 300 clinical samples tested with strong performance results. In House Lab process validated. Manufacturing-grade kits validated. Read: https://t.co/p2ey3D9ZTw $RHY

Long Shortz with @rhythmbiosc : $3.75M placement to accelerate cancer and genetic diagnostics https://t.co/pVmJw3nA5N hashtag#ASX hashtag#Health $RHY

NEWS: $3.75M raise at $0.09 per share to advance ColoSTAT® launch and geneType™ commercialisation. Strong investor demand with Directors contributing $0.3m showing continued confidence. "It's a huge privilege to help in the battle against cancer" - CEO Dr David Atkins $RHY

Runner of the Week from @BullsNBearsWA highlights ColoSTAT® progress. Clinical study of 300 patients showed consistent colorectal #cancer detection across all stages. "This biotech minnow could help rewrite the script on cancer screening." Read: https://t.co/bllKQuE5dw $RHY

#Prostatecancer affects 1 in 6 Australian men. geneType™'s risk assessment combines genetic factors with clinical history to inform personalised PSA screening decisions. Helping healthcare providers discuss individualised approaches with male patients https://t.co/4zXaT2onKe